Prevention of Type 1 Diabetes

Pediatric Clinics of North America

Volumn 58, Issue 5, 2011, Pages 1257-1270

  Wherrett, Diane K ^a   Daneman, Denis ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Autoimmunity; Clinical trials; Genetics; Immunology; Prevention; Type 1 diabetes

Indexed keywords

ABATACEPT; AZATHIOPRINE; C PEPTIDE; CANAKINUMAB; CYCLOSPORIN; DACLIZUMAB; DOCOSAHEXAENOIC ACID; ETANERCEPT; GLUTAMATE DECARBOXYLASE; INSULIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OMEGA 3 FATTY ACID; OTELIXIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; VITAMIN D;

ADULT; AUTOIMMUNITY; BREAST FEEDING; CHILD; DRUG DOSE REDUCTION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PREDICTION; PRIMARY PREVENTION; REHABILITATION; REVIEW; SECONDARY PREVENTION;

EID: 80053603300     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2011.07.010     Document Type: Review

References (71)

1. Devendra D., Liu E., Eisenbarth G.S., et al. Type 1 diabetes: recent developments. BMJ 2004, 328(7442):750-754.
2. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986, 314(21):1360-1368.
3. Akerblom H.K., Vaarala O., Hyoty H., et al. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002, 115(1):18-29.
4. Helgason T., Jonasson M.R. Evidence for a food additive as a cause of ketosis-prone diabetes. Lancet 1981, 2(8249):716-720.
5. Thorsdottir I., Ramel A. Dietary intake of 10- to 16-year-old children and adolescents in central and northern Europe and association with the incidence of type 1 diabetes. Ann Nutr Metab 2003, 47(6):267-275.
6. Vaarala O., Knip M., Paronen J., et al. Cow's milk formula feeding induces primary immunization to insulin in infants at genetic risk for type 1 diabetes. Diabetes 1999, 48(7):1389-1394.
7. Virtanen S.M., Laara E., Hypponen E., et al. Cow's milk consumption, HLA-DQB1 genotype, and type 1 diabetes: a nested case-control study of siblings of children with diabetes. Childhood diabetes in Finland study group. Diabetes 2000, 49(6):912-917. [erratum appears in Diabetes 2000;49(9):1617].
8. Barker J.M., Yu J., Yu L., et al. Autoantibody " subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care 2005, 28(4):850-855.
9. Daneman D. State of the world's children with diabetes. Pediatr Diabetes 2009, 10(2):120-126.
10. International Diabetes Federation Diabetes atlas 2006, 3rd edition, International Diabetes Federation, (Belgium), Available at:. http://www.eatlas.idf.org, Brussels.
11. Tuomilehto J., Karvonen M., Pitkaniemi J., et al. Record-high incidence of type I (insulin-dependent) diabetes mellitus in Finnish children. The Finnish Childhood Type I Diabetes Registry Group. Diabetologia 1999, 42(6):655-660.
12. Raymond N.T., Jones J.R., Swift P.G., et al. Comparative incidence of type I diabetes in children aged under 15 years from South Asian and White or other ethnic backgrounds in Leicestershire, UK, 1989 to 1998. Diabetologia 2001, 44(Suppl 3):B32-B36.
13. Kondrashova A., Reunanen A., Romanov A., et al. A six-fold gradient in the incidence of type 1 diabetes at the eastern border of Finland. Ann Med 2005, 37(1):67-72.
14. Gillespie K.M., Bain S.C., Barnett A.H., et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004, 364(9446):1699-1700.
15. Redondo M.J., Eisenbarth G.S. Genetic control of autoimmunity in type I diabetes and associated disorders. Diabetologia 2002, 45(5):605-622.
16. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358(9277):221-229.
17. Achenbach P., Bonifacio E., Koczwara K., et al. Natural history of type 1 diabetes. Diabetes 2005, 54(Suppl 2):S25-31.
18. Huber A., Menconi F., Corathers S., et al. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr Rev 2008, 29(6):697-725.
19. Barker J.M. Clinical review: type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006, 91(4):1210-1217.
20. Cooper J.D., Smyth D.J., Smiles A.M., et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 2008, 40(12):1399-1401.
21. Barrett J.C., Clayton D.G., Concannon P., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009, 41:703-707.
22. Ball T.M., Castro-Rodriguez J.A., Griffith K.A., et al. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 2000, 343(8):538-543.
23. Betts P., Mulligan J., Ward P., et al. Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2). Diabet Med 2005, 22(2):144-151.
24. Daneman D. Is the 'Accelerator Hypothesis' worthy of our attention?. Diabet Med 2005, 22(2):115-117.
25. Gale E.A. A missing link in the hygiene hypothesis?. Diabetologia 2002, 45(4):588-594.
26. Kaila B., Taback S.P. The effect of day care exposure on the risk of developing type 1 diabetes: a meta-analysis of case-control studies. Diabetes Care 2001, 24(8):1353-1358.
27. von Mutius E., Martinez F.D., Fritzsch C., et al. Skin test reactivity and number of siblings. BMJ 1994, 308(6930):692-695.
28. Wilkin T.J. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 2001, 44(7):914-922.
29. Group T.S. The environmental determinants of diabetes in the young (TEDDY) study. Ann N Y Acad Sci 2008, 1150:1-13.
30. Merriman T.R., Merriman T.R. Type 1 diabetes, the A1 milk hypothesis and vitamin D deficiency. Diabetes Res Clin Pract 2009, 83(2):149-156.
31. Group T.S. Study design of the trial to reduce IDDM in the genetically at risk (TRIGR). Pediatr Diabetes 2007, 8(3):117-137.
32. Knip M., Virtanen S.M., Seppä K., et al. Dietary Intervention in Infancy and Later Signs of Beta-Cell Autoimmunity. N Engl J Med 2010, 363:1900-1908.
33. Chase H.P., Lescheck E., Rafkin-Mervis L., et al. Nutritional Intervention to Prevent (NIP) type 1 diabetes a Pilot Trial. ICAN: Infant, Child, Adolescent Nutrition 2009, 1(2):98-107.
34. Norris J.M., Yin X., Lamb M.M., et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007, 298(12):1420-1428.
35. Schmid S., Buuck D., Knopff A., et al. BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten. Diabetologia 2004, 47(6):1130-1131.
36. Bonifacio E., Hummel M., Hummel S., et al. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: The BABYDIET study. Diabetes Care 2011, 34(6):1301-1305.
37. Norris J.M., Barriga K., Klingensmith G., et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003, 290(13):1713-1720.
38. Moro J.R., Iwata M., von Andriano U.H., et al. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008, 8(9):685-698.
39. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008, 93(6):512-517.
40. Wenzlau J.M., Juhl K., Yu L., et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007, 104(43):17040-17045.
41. Verge C.F., Gianani R., Kawasaki E., et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996, 9(3):379-383.
42. Sosenko J.M., Palmer J.P., Greenbaum C.J., et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention trial-type 1. Diabetes Care 2006, 29(3):643-649.
43. Mahon J.L., Sosenko J.M., Rafkin-Mervis L., et al. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009, 10(2):97-104.
44. Gale E.A., Bingley P.J., Emmett C.L., et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363(9413):925-931.
45. Diabetes Prevention Trial-Type 1 Diabetes Study Group Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002, 346(22):1685-1691.
46. Skyler J.S., Krischer J.P., Wolfsdorf J., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005, 28(5):1068-1076.
47. Nanto-Salonen K., Kupila A., Simell S., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372(9651):1746-1755.
48. Achenbach P., Barker J., Bonifacio E., et al. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008, 8(2):87-93.
49. Harrison L.C., Honeyman M.C., Steele C.E., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27(10):2348-2355.
50. Bonfanti R., Bazzigaluppi E., Calori G., et al. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 1998, 15(10):844-850.
51. Sochett E.B., Daneman D., Clarson C., et al. Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia 1987, 30(7):453-459.
52. Pozzilli P., Manfrini S., Buzzetti R., et al. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabetes Res Clin Pract 2005, 68(3):258-264.
53. Yki-Jarvinen H., Koivisto V.A. Natural course of insulin resistance in type I diabetes. N Engl J Med 1986, 315(4):224-230.
54. Palmer J.P., Fleming G.A., Greenbaum C.J., et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004, 53(1):250-264. [Erratum appears in Diabetes 2004;53(7):1934].
55. Steffes M.W., Sibley S., Jackson M., et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003, 26(3):832-836.
56. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 1988, 37(11):1574-1582.
57. Feutren G., Papoz L., Assan R., et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986, 2(8499):119-124.
58. Harrison L.C., Colman P.G., Dean B., et al. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985, 34(12):1306-1308.
59. Silverstein J., Maclaren N., Riley W., et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988, 319(10):599-604.
60. Chatenoud L., Bluestone J.A., Chatenoud L., et al. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007, 7(8):622-632.
61. Herold K.C., Gitelman S.E., Masharani U., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type1 diabetes. Diabetes 2005, 54(6):1763-1769.
62. Herold K.C., Hagopian W., Auger J.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002, 346(22):1692-1698.
63. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352(25):2598-2608.
64. Sherry N., Hagopian W., Ludvigsson J., et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. The Lancet 2011, 378(9790):487-497.
65. Levesque M.C., St Clair E.W., Levesque M.C., et al. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008, 121(1):13-21. [quiz 22-3].
66. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361(22):2143-2152.
67. Orban T., Bundy B., Becker D.J., et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. The Lancet 2011, 378(9789):412-419.
68. Tisch R., Wang B., Serreze D.V. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 1999, 163(3):1178-1187.
69. Ludvigsson J., Faresjo M., Hjorth M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359(18):1909-1920.
70. Wherrett D.K., Bundy B., Becker D.J., et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. The Lancet 2011, 378(9788):319-327.
71. Mastrandrea L., Yu J., Behrens T., et al. Etanercept treatment in children with new onset type 1 diabetes: pilot randomized, placebo-controlled, double blind study. Diabetes Care 2009, 32(7):1244-1249.